Osteosarcoma after allogennic bone marrow transplantation. A report of four cases from the Cooperative Osteosarcoma Study Group (COSS)

Bone Marrow Transplantation

Volumn 31, Issue 5, 2003, Pages 353-359

  Bielack, S S ^a   Rerin, J S ^a   Dickerhoff, R ^b   Dilloo, D ^c   Kremens, B ^d   von Stackelberg, A ^e   Vormoor, J ^a   Jurgens H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Johanniter Kinderklinik ^*  (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bone marrow transplantation; Neoplasms (second primary); Osteosarcoma

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GROWTH HORMONE; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; TROFOSFAMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANAPHYLAXIS; ARTICLE; BONE MARROW CELL; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CHILD; CONTROLLED STUDY; DATA BASE; FEMALE; GRAFT VERSUS HOST REACTION; GROWTH DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KNEE DISEASE; MALE; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; OSTEOSARCOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SURVIVAL TIME; TREATMENT INDICATION; WHOLE BODY RADIATION; ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; BONE TUMOR; HISTOCOMPATIBILITY TEST; SECOND CANCER;

ANEMIA, SICKLE CELL; BONE MARROW TRANSPLANTATION; BONE NEOPLASMS; CHILD; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; NEOPLASMS, SECOND PRIMARY; OSTEOSARCOMA;

EID: 0037354258     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703864     Document Type: Article

References (38)

1. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833-1844.
2. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
3. Kolb HJ, Socie G, Duell T et al. Malignant neoplasms in longterm survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738-744.
4. Bhatia S, Louie AD, Bhatia R et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 15: 464-471.
5. Hawkins MM, Wilson LM, Burton HS et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88: 270-278.
6. Socie G, Curtis RE, Deeg HJ et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348-357.
7. Favre-Schmuziger G, Hofer S, Passweg J et al. Treatment of solid tumors following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 895-898.
8. Kirova YM, Rafi H, Voisin MC et al. Radiation-induced bone sarcoma following total body irradiation: role of additional radiation on localized areas. Bone Marrow Transplant 2000; 25: 1011-1013.
9. Bielack S, Kempf-Bielack B, Schwenzer D et al. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudien-gruppe COSS an 925 Patienten. Klin Radiatr 1999; 211: 260-270.
10. Bielack S, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk. An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2002; 20: 776-790.
11. Kaatsch P, Kaletsch U, Spix C et al. Jahresbericht 1998. Deutsches Kinderkrebsregister. Mainz, Johannes-Gutenberg-Universität, Institut für Medizinische Statistik und Information, 1999.
12. Schrappe M, Reiter A, Zimmermann M et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000; 14: 2205-2222.
13. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239.
14. Bührer C, Hartmann R, Fengler R et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group. J Clin Oncol 1996; 14: 2812-2817.
15. Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologie 1983; 4: 135-141.
16. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342 352.
17. Cahan WG, Woodard HQ, Higinbotham NL et al. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer 1998; 82: 8-34.
18. Meadows AT, Strong LC, Li FP et al. Bone sarcoma as a second malignant neoplasm in children: influence of radiation and genetic predisposition for the Late Effects Study Group. Cancer 1980; 46: 2603-2606.
19. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 1987; 56: 339-347.
20. Tucker MA, D'Angio GJ, Boice Jr JD et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588-593.
21. Le Vu B, de Vathaire F, Shamsaldin A et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998; 77: 370-377.
22. Ferrari C, Bohling T, Benassi MS et al. Secondary tumors in bone sarcomas after treatment with chemotherapy. Cancer Detect Prev 1999; 23: 368-374.
23. Nygaard R, Garwicz S, Haldorsen T et al. Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. The Nordic Society of Pediatric Oncology and Hematology (NOPHO). Acta Paediatr Scand 1991; 80: 1220-1228.
24. Neglia JP, Meadows AT, Robison LL et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330-1336.
25. Löning L, Zimmermann M, Reiter A et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000; 95: 2770-2775.
26. Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Int Med 1969; 71: 747-752.
27. Kleihues P, Schauble B, zur Hausen A et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997; 150: 1-13.
28. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
29. Srivastava S, Zou ZQ, Pirollo K et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
30. McIntyre JF, Smith-Sorensen B, Friend SH et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994; 12: 925-930.
31. Russo CL, McIntyre J, Goorin AM et al. Secondary breast cancer in patients presenting with osteosarcoma: possible involvement of germline p53 mutations. Med Pediatr Oncol 1994; 23: 354-358.
32. Pratt CB, Meyer WH, Luo X et al. Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997; 80: 960-965.
33. Nichols KE, Malkin D, Garber JE et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001; 10: 83-87.
34. Mantadakis E, Rogers ZR, Smith AK et al. Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma. J Pediatr Hematol Oncol 1999; 21: 165-169.
35. Mirra JM, Gold RH, Marafiote R. Malignant (fibrous) histiocytoma arising in association with a bone infarct in sickle-cell disease: coincidence or cause-and-effect? Cancer 1977; 39: 186-194.
36. Dawkins FW, Kim KS, Squires RS et al. Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986-1995. Am J Hematol 1997; 55: 188-192.
37. Bielack S, Kempf-Bielack B, Heise U et al. Combined modality treatment for osteosarcoma occurring as a second malignant disease. J Clin Oncol 1999; 17: 1164-1174.
38. Tabone MD, Terrier P, Pacquement H et al. Outcome of radiation-related osteosarcoma after treatment of childhood and adolescent cancer: a study of 23 cases. J Clin Oncol 1999; 17: 2789-2795.